ENPP1 and Insulin resistance: A gain-of-function mutation in ectonucleotide pyrophosphatase/phosphodiesterase1 (ENPP1) inhibits insulin receptor activity, resulting in insulin resistance and accelerated liver fibrosis in a cohort of obese NAFLD patients[99].